• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Diagnostic and therapeutic strategy in lung cancer].

作者信息

Rozensztajn Nathalie, Créquit Perrine, Wislez Marie, Cadranel Jacques

机构信息

Service de pneumologie, centre expert en oncologie thoracique, AP-HP, hôpital Tenon, Paris, France.

出版信息

Rev Prat. 2017 Jan;67(1):40-46.

PMID:30512432
Abstract

Diagnostic and therapeutic strategy in lung cancer. Clinical signs that must lead a clinician to suspect lung cancer are non-specific, but are often linked to the appearance or modification of a respiratory or general symptom. When lung cancer is suspected, the following informations must be obtained through diagnostic assessment: histological proof of cancer, tumoral extension and comorbidities. Therapeutic strategy depends on the distinction between small-cell and non-smallcell lung cancer, and on tumoral extension. In the case of a localized carcinoma, the determinant item for therapeutic decision is operability. In advanced non-small-cell carcinoma, distinction between squamous and non-squamous lung cancer, and the presence of molecular anomalies guide the therapy. In spite of therapeutic advances (targeted therapies, immunotherapy), the treatment of the majority of patients relies on chemotherapy.

摘要

相似文献

1
[Diagnostic and therapeutic strategy in lung cancer].
Rev Prat. 2017 Jan;67(1):40-46.
2
SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015.2015年SEOM非小细胞肺癌(NSCLC)治疗临床指南
Clin Transl Oncol. 2015 Dec;17(12):1020-9. doi: 10.1007/s12094-015-1455-z. Epub 2015 Dec 21.
3
Lung cancer.肺癌
Cas Lek Cesk. 2018 Fall;157(5):226-236.
4
The changing diagnostic pathway for lung cancer patients in Shanghai, China.中国上海肺癌患者诊断途径的变化
Eur J Cancer. 2017 Oct;84:168-172. doi: 10.1016/j.ejca.2017.07.036. Epub 2017 Aug 17.
5
[Therapeutic impact of molecular diagnosis in metastatic non-small cell lung cancer: targeted therapies in 2013].[分子诊断在转移性非小细胞肺癌中的治疗影响:2013年的靶向治疗]
Rev Pneumol Clin. 2014 Feb-Apr;70(1-2):38-46. doi: 10.1016/j.pneumo.2013.12.005. Epub 2014 Feb 22.
6
Non small cell lung cancer (NSCLC): current status and future prospects.非小细胞肺癌(NSCLC):现状与未来展望。
Indian J Chest Dis Allied Sci. 2004 Jul-Sep;46(3):191-203.
7
Targeted Therapy and Immunotherapy in the Treatment of Non-Small Cell Lung Cancer.非小细胞肺癌治疗中的靶向治疗与免疫治疗
Radiol Clin North Am. 2018 May;56(3):485-495. doi: 10.1016/j.rcl.2018.01.012.
8
Management of non-small cell lung cancer in the era of personalized medicine.个性化医疗时代的非小细胞肺癌管理
Int J Biochem Cell Biol. 2016 Sep;78:173-179. doi: 10.1016/j.biocel.2016.07.011. Epub 2016 Jul 15.
9
[Therapeutic strategies in patients undergoing surgery for non-small cell lung cancer. Results of the ESCAP-2011-CPHG study, promoted by the French College of General Hospital Respiratory Physicians (CPHG)].[非小细胞肺癌手术患者的治疗策略。由法国综合医院呼吸内科医师学会(CPHG)推动的ESCAP - 2011 - CPHG研究结果]
Rev Mal Respir. 2017 Nov;34(9):976-990. doi: 10.1016/j.rmr.2017.05.002. Epub 2017 Nov 15.
10
[Prolonged response with paclitaxel after immunotherapy by pembrolizumab in lung cancer].[帕博利珠单抗免疫治疗后肺癌患者对紫杉醇的延长反应]
Rev Pneumol Clin. 2016 Oct;72(5):300-304. doi: 10.1016/j.pneumo.2016.05.004. Epub 2016 Aug 22.